Meanwhile, as the therapeutic benefit of programmed cell death receptor 1 (PD-1) inhibitor was weakened in Mettl3−/− mice, METTL3 could be a potential target for tumor immunotherapy. This evidence concerns the gene METTL3 and neoplasm.